Alaunos TherapeuticsTCRT
Market Cap: $4.52M
About: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Employees: 34
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,167% more call options, than puts
Call options by funds: $68K | Put options by funds: $3K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
9% more funds holding
Funds holding: 46 [Q1] → 50 (+4) [Q2]
0.43% more ownership
Funds ownership: 14.75% [Q1] → 15.18% (+0.43%) [Q2]
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
60% less capital invested
Capital invested by funds: $4.26M [Q1] → $1.71M (-$2.56M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TCRT.